Background: Asprosin, a new adipocytokine, has reportedly been associated with glucose release, dyslipidemia, and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aimed to investigate the correlation between serum asprosin levels and the factors influencing metabolic syndrome. Patients and Methods: This is a case control study was conducted on 100 children who attended and were selected from the General Pediatrics Outpatient Clinic, Zagazig University Hospital during the period of the study. Children were divided into two groups; Group1: included 50 obese children and Group 2: included 50 healthy normal weight children of matched age and sex. Results: Regarding to serum asprosin there was highly significant increase in obese group compared and control group. There were significant positive correlations between serum asprosin and weight, body mass index (BMI), waist circumference, systolic blood pressure (SBP), total cholesterol, triglycerides, fasting blood glucose (FBG), homeostasis model assessment (HOMA-IR) and glycosylated hemoglobin (HbA1c). There were significant negative correlations between serum asprosin and height, DBP and fasting insulin level. Conclusions: this study suggest a direct correlation between elevated levels of asprosin and key indicators of obesity and metabolic syndrome highlights its potential role in contributing to the complex web of metabolic dysregulation